

PROTAC CBP/P300 Degradar-1 Biochemical

PROTAC CBP/P300 Degradar-1

CATALOG #
AAA228470


PRODUCT SYNONYMS

PROTAC CBP/P300 Degradar-1; PROTAC CBP/P300 Degradar-1 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	2484739-48-0
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	PROTAC CBP/P300 Degradar-1 shows LNCaP prostate cancer cell viability inhibition (IC ₅₀ = 0.4 nM). PROTAC CBP/P300 Degradar-1 (10 nM) induces degradation of P300 (>= 80%)[1]. PROTAC CBP/P300 Degradar-1 potently inhibited cell viability of multiple cancer cell lines (IC ₅₀ s ranging from 0.1-141.4 nM for HEL, NOMO-1, MOLM-13, HL-60, MEG-01, MM.1S, MM.1R, NCL-H929, RPM-8226, AMO-1, WSU-DLCL2, Karpas-422, Pfeiffer, SU-DHL-1, LNCaP clone FGC, VCap; 22RV1, NCI-H520, NCI-H703, LK-2, MCE-7, and SK-BR-3 cells)[1].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
LyP-1, CAS 454487-07-1



Structure
LyP-1, CAS 454487-07-1

ADDITIONAL INFORMATION

Related Product Information for PROTAC CBP/P300 Degradar-1 biochemical	PROTAC CBP/P300 Degradar-1 is a potent PROTAC CBP/P300 degrader. PROTAC CBP/P300 Degradar-1 potently inhibited cell viability of multiple cancer cell lines.
References	1. Fan Zhang, et al. Imaging tumor-induced sentinel lymph node lymphangiogenesis with LyP-1 peptide. Amino Acids. 2012 Jun;42(6):2343-51. 2. Ningning Song, et al. Recent progress in LyP-1-based strategies for targeted imaging and therapy. Drug Deliv. 2019 Dec;26(1):363-375.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://stage.aaabiotech.com/biochemical/protac-cbp-p300-degrader-1/228470>